Halozyme Therapeutics, Inc. (0J2O)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 125.42 |
|---|---|
| 52-week range | 59.85 – 127.76 |
| Return, 1 month / 3 months | +11.2% / +56.6% |
| Return, 1 year / 3 years | – / – |
| Trend | Uptrend |
| RSI (14) | 71 |
| Volatility (1 year) | 38.9% |
| Worst drawdown (1 year) | -24.0% |
| Average daily value traded | 0.14M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Halozyme Therapeutics is a biopharmaceutical company based in San Diego, California, that develops enzyme-based products for drug delivery. Its main technology, ENHANZE, uses a recombinant human hyaluronidase enzyme to help other medicines be given as subcutaneous injections rather than intravenous infusions. The company licenses this technology to pharmaceutical partners and also markets its own enzyme products and drug-delivery devices. Its customers are mainly drug developers and healthcare providers.
The shares are listed on the London Exchange in UK under the code 0J2O, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Halozyme Therapeutics, Inc. (0J2O) trades on the London Exchange in UK. It last closed at USD 125.42 on 23 October 2026.
Its price-based Market X-Ray is 75 out of 100 (a strong price profile), ranking 273 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 98 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 52.9% | ||
| From 52-week high | 0.0% | ||
| Momentum | 98 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 56.6% | ||
| 6-month return | 86.7% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 38.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.0% | ||
| Liquidity | 33 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.14M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +3.7% |
|---|---|
| 1 month | +11.2% |
| 3 months | +56.6% |
| 6 months | +86.7% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 111.21 / 82.02 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.29 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.